漢達生技醫藥股份有限公司
漢達生技醫藥股份有限公司是一家特用藥業公司,專注於在美國開發多種疾病藥物。公司提供 ONCORE 專利藥物傳輸技術,旨在提高腫瘤藥物激酶抑制劑的患者依從性與安全性;以及 Tascenso ODT(多發性硬化症治療)、HND-033/039/027(腫瘤用藥)。亦提供 Quetiapine XR(精神分裂症)、Dexlansoprazole(胃食道逆流)及戒菸藥物 HND-032。公司成立於 2014 年,總部位於台灣台南市。
今日下跌 4.62%,股價跌破短期均線。該股 RSI(6) 為 45.2,處於中性區間,短線無明顯超買超賣訊號。股價站上20日、60日、120日均線,跌破5日均線。短中期均線呈多頭排列,趨勢偏多。KD 指標中性(K=38.4);MACD 柱狀體為負值,空方動能持續。 (自動產生 · 非投資建議)
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | +92 | 0 | +172 | +198 |
| 09-23 | -751 | 0 | +176 | -679 |
| 09-22 | +470 | 0 | +53 | +416 |
| 09-21 | -1,528 | +400 | +16 | -1,235 |
| 09-18 | +542 | +232 | +292 | +644 |
| 09-17 | +285 | 0 | +26 | +235 |
| 09-16 | +108 | 0 | +27 | +45 |
| 09-15 | +45 | 0 | +203 | +146 |
| 09-14 | +45 | 0 | +28 | +49 |
| 09-11 | -69 | 0 | +46 | -66 |
| 09-10 | -3 | 0 | 0 | -9 |
| 09-09 | -37 | 0 | +129 | +30 |
| 09-08 | +818 | +240 | +81 | +1,058 |
| 09-07 | +719 | +173 | +425 | +1,046 |
| 09-04 | +669 | 0 | +243 | +675 |
| 09-03 | +56 | 0 | +295 | +119 |
| 09-02 | +534 | 0 | +145 | +568 |
| 09-01 | -62 | 0 | +182 | -38 |
| 08-31 | -23 | 0 | +115 | +34 |
| 08-28 | +47 | 0 | +166 | +121 |
| 08-27 | +6 | 0 | +70 | +19 |
| 08-26 | +29 | 0 | +34 | +45 |
| 08-25 | -114 | 0 | +10 | -143 |
| 08-24 | +49 | 0 | +14 | +54 |
| 08-21 | -9 | 0 | 0 | -12 |
| 08-20 | +27 | 0 | +10 | +31 |
| 08-19 | -65 | 0 | 0 | -112 |
| 08-18 | +35 | 0 | +26 | +31 |
| 08-17 | -6 | 0 | +36 | +9 |
| 08-14 | -110 | 0 | +3 | -122 |
| 08-13 | -13 | 0 | +14 | -13 |
| 08-12 | -32 | 0 | +18 | -28 |
| 08-11 | +142 | 0 | +6 | +34 |
| 08-10 | -224 | 0 | 0 | -551 |
| 08-07 | -94 | 0 | +4 | -101 |
| 08-06 | -170 | 0 | 0 | -197 |
| 08-05 | +60 | 0 | +104 | +148 |
| 08-04 | +36 | 0 | +77 | +71 |
| 08-03 | -153 | 0 | +62 | -269 |
| 07-31 | +192 | 0 | +160 | +184 |
| 07-30 | -20 | 0 | +18 | -9 |
| 07-29 | +118 | 0 | +181 | +192 |
| 07-28 | -42 | 0 | +31 | -29 |
| 07-27 | -57 | 0 | +67 | -26 |
| 07-24 | +10 | 0 | +9 | +12 |
| 07-23 | -56 | 0 | +5 | -74 |
| 07-22 | +3 | 0 | +145 | +73 |
| 07-21 | -185 | 0 | +182 | -100 |
| 07-20 | -69 | 0 | +79 | -30 |
| 07-17 | -56 | 0 | +67 | -29 |
| 07-16 | -160 | 0 | +77 | -125 |
| 07-15 | -337 | 0 | +62 | -309 |
| 07-14 | +184 | 0 | +82 | +165 |
| 07-13 | +28 | 0 | +70 | +72 |
| 07-09 | -3 | 0 | +8 | -69 |
| 07-08 | +5 | 0 | +8 | +8 |
| 07-07 | -17 | 0 | +18 | -29 |
| 07-06 | +41 | 0 | +54 | +68 |
| 07-03 | +70 | 0 | +16 | +68 |
| 07-02 | -2 | 0 | +14 | +5 |
| 07-01 | +20 | 0 | +6 | +23 |
| 06-30 | +7 | 0 | +14 | +14 |
| 06-29 | 0 | 0 | +30 | +12 |
| 06-26 | +86 | 0 | +2 | +78 |
| 06-25 | -272 | 0 | +143 | -294 |
| 06-24 | +135 | 0 | +375 | +317 |
| 06-23 | -242 | 0 | +380 | -88 |
| 06-22 | -30 | 0 | +17 | -30 |
| 06-18 | +157 | 0 | +284 | +291 |
| 06-17 | +123 | 0 | +121 | +183 |
| 06-16 | -99 | 0 | +84 | -70 |
| 06-15 | +88 | 0 | +185 | +172 |
| 06-12 | -262 | 0 | +24 | -251 |
| 06-11 | -87 | 0 | +6 | -86 |
| 06-10 | +102 | 0 | +186 | +193 |
| 06-09 | -99 | 0 | +27 | -84 |
| 06-08 | -49 | 0 | +94 | -7 |
| 06-05 | +9 | 0 | +43 | +31 |
| 06-04 | -26 | 0 | +50 | -1 |
| 06-03 | +39 | 0 | +13 | +44 |
| 06-02 | -8 | 0 | 0 | -8 |
| 06-01 | +121 | 0 | +13 | +128 |
| 05-29 | -37 | 0 | +13 | -30 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 6207 萬 | -21.1% | - |
| 2026/03 | 7872 萬 | +43.2% | - |
| 2026/02 | 5497 萬 | -27.4% | - |
| 2026/01 | 7569 萬 | -44.7% | - |
| 2025/12 | 1.37 億 | +80.5% | - |
| 2025/11 | 7580 萬 | -13.4% | - |
| 2025/10 | 8758 萬 | - | - |